Skip to content
value.today

TAS Medical, Inc.

🇺🇸 Windermere, Florida, USATechnologyFounded 2017
Total raised
$13 M
3 rounds on record
Latest round
$4 M
Mar 2026
First round on record
Oct 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of TAS Medical, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2026$4 MNo. 3$2 to $10 million

TAS Medical, Inc.: Raise no. 3, Mar 2026

Investors in this round

17 investors had bought by the notice of Apr 10, 2026: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $7 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Albert K. Chin · Executive Officer, Director
  • Jon A. Freeman · Executive Officer
  • Michael J. Tozzi · Executive Officer, Director
  • Thomas A. Kramer · Executive Officer, Director
  • John A. Dwyer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “13(a) and (c) include warrants to purchase up to 1,105,640 shares of preferred stock, which may never be exercised.”

Signed by Michael J. Tozzi, Chief Executive Officer. Newest notice filed Apr 10, 2026. Read the notice at the SEC.

equity, optionsSEC
Aug 2024$4 MNo. 2$2 to $10 million

TAS Medical, Inc.: Raise no. 2, Aug 2024

Investors in this round

21 investors had bought by the notice of Aug 17, 2026: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Albert K. Chin · Executive Officer, Director
  • Michael J. Tozzi · Executive Officer, Director
  • Thomas A. Kramer · Executive Officer, Director
  • John A. Dwyer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The offering is complete. 13(a) and (c) include warrants to purchase up to 234,708 shares of common stock, which may never be exercised.”

Signed by Michael J. Tozzi, Chief Executive Officer. Newest notice filed Aug 17, 2026. Read the notice at the SEC.

equity, optionsSEC
Oct 2020$5 MNo. 1$2 to $10 million

TAS Medical, Inc.: Raise no. 1, Oct 2020

Investors in this round

46 investors had bought by the notice of Nov 13, 2020: 46 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $8 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Albert K. Chin · Executive Officer, Director
  • Michael J. Tozzi · Executive Officer, Director, Promoter
  • Thomas A. Kramer · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount and Total Amount Sold includes $2,778,137 which represents the conversion of convertible promissory notes and accrued interest.”

Signed by Michael J. Tozzi, Chief Executive Officer. Newest notice filed Nov 13, 2020. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • TAS Medical, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2026).

    SEC Form D · Aug 2026

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Apr 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of TAS Medical, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by TAS Medical, Inc.
NameRoleNamed in
Albert K. ChinExecutive officerAug 2026
Michael J. TozziExecutive officerAug 2026
Thomas A. KramerExecutive officerAug 2026
Jon A. FreemanExecutive officerApr 2026
Albert K. ChinDirectorAug 2026
John A. DwyerDirectorAug 2026
Michael J. TozziDirectorAug 2026
Thomas A. KramerDirectorAug 2026
Michael J. TozziPromoterNov 2020